Q-omics provides the consensus-scored UPF3A profile across patient tissues and cancer cell-line models. UPF3A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, UPF3A is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, UPF3A RNA expression shows 20,783 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, THCA, and UVM as cancer lineages where UPF3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UPF3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UPF3A survival associations across molecular data types. UPF3A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UPF3A RNA expression–survival associations across cancer types. High UPF3A expression shows unfavorable associations in ACC, CESC, LIHC and UVM, but favorable associations in PAAD and STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for UPF3A RNA expression.
This table summarizes UPF3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for UPF3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UPF3A shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, COAD, CHOL and STAD. The THCA box plot shows higher UPF3A RNA expression in normal versus tumor tissue (log2 FC = −0.742, t-test p < 0.001).
This table shows molecular features associated with UPF3A in patient tissues and cancer cell lines. In patient samples, UPF3A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, UPF3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
